429 related articles for article (PubMed ID: 34861168)
1. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.
Bowman SJ; Fox R; Dörner T; Mariette X; Papas A; Grader-Beck T; Fisher BA; Barcelos F; De Vita S; Schulze-Koops H; Moots RJ; Junge G; Woznicki JN; Sopala MA; Luo WL; Hueber W
Lancet; 2022 Jan; 399(10320):161-171. PubMed ID: 34861168
[TBL] [Abstract][Full Text] [Related]
2. Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity.
Dörner T; Posch MG; Li Y; Petricoul O; Cabanski M; Milojevic JM; Kamphausen E; Valentin MA; Simonett C; Mooney L; Hüser A; Gram H; Wagner FD; Oliver SJ
Ann Rheum Dis; 2019 May; 78(5):641-647. PubMed ID: 30826774
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study.
Fisher BA; Szanto A; Ng WF; Bombardieri M; Posch MG; Papas AS; Farag AM; Daikeler T; Bannert B; Kyburz D; Kivitz AJ; Carsons SE; Isenberg DA; Barone F; Bowman SJ; Espié P; Floch D; Dupuy C; Ren X; Faerber PM; Wright AM; Hockey HU; Rotte M; Milojevic J; Avrameas A; Valentin MA; Rush JS; Gergely P
Lancet Rheumatol; 2020 Mar; 2(3):e142-e152. PubMed ID: 38263652
[TBL] [Abstract][Full Text] [Related]
4. Development and Application of the Placebo Response Model in Clinical Trials for Primary Sjögren's Syndrome.
Wang ZZ; Zheng QS; Liu HX; Li LJ
Front Immunol; 2021; 12():783246. PubMed ID: 34868062
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial.
Dörner T; Kaul M; Szántó A; Tseng JC; Papas AS; Pylvaenaeinen I; Hanser M; Abdallah N; Grioni A; Santos Da Costa A; Ferrero E; Gergely P; Hillenbrand R; Avrameas A; Cenni B; Siegel RM
Ann Rheum Dis; 2024 Feb; 83(3):360-371. PubMed ID: 37932009
[TBL] [Abstract][Full Text] [Related]
6. Leflunomide-hydroxychloroquine combination therapy in patients with primary Sjögren's syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial.
van der Heijden EHM; Blokland SLM; Hillen MR; Lopes APP; van Vliet-Moret FM; Rosenberg AJWP; Janssen NG; Welsing PMJ; Iannizzotto V; Tao W; Pandit A; Barone F; Kruize AA; Radstake TRDJ; van Roon JAG
Lancet Rheumatol; 2020 May; 2(5):e260-e269. PubMed ID: 38273473
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trial.
Baer AN; Gottenberg JE; St Clair EW; Sumida T; Takeuchi T; Seror R; Foulks G; Nys M; Mukherjee S; Wong R; Ray N; Bootsma H
Ann Rheum Dis; 2021 Mar; 80(3):339-348. PubMed ID: 33168545
[TBL] [Abstract][Full Text] [Related]
8. Abatacept treatment for patients with early active primary Sjögren's syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study).
van Nimwegen JF; Mossel E; van Zuiden GS; Wijnsma RF; Delli K; Stel AJ; van der Vegt B; Haacke EA; Olie L; Los LI; Verstappen GM; Pringle SA; Spijkervet FKL; Kroese FGM; Vissink A; Arends S; Bootsma H
Lancet Rheumatol; 2020 Mar; 2(3):e153-e163. PubMed ID: 38263653
[TBL] [Abstract][Full Text] [Related]
9. Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial.
Felten R; Devauchelle-Pensec V; Seror R; Duffau P; Saadoun D; Hachulla E; Pierre Yves H; Salliot C; Perdriger A; Morel J; Mékinian A; Vittecoq O; Berthelot JM; Dernis E; Le Guern V; Dieudé P; Larroche C; Richez C; Martin T; Zarnitsky C; Blaison G; Kieffer P; Maurier F; Dellal A; Rist S; Andres E; Contis A; Chatelus E; Sordet C; Sibilia J; Arnold C; Tawk MY; Aberkane O; Holterbach L; Cacoub P; Saraux A; Mariette X; Meyer N; Gottenberg JE
Ann Rheum Dis; 2021 Mar; 80(3):329-338. PubMed ID: 33208345
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of telitacicept in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial.
Xu D; Fang J; Zhang S; Huang C; Huang C; Qin L; Li X; Chen M; Liu X; Liu Y; Li Z; Hu J; Bao C; Wei W; Tian J; Duan X; Zeng X
Rheumatology (Oxford); 2024 Mar; 63(3):698-705. PubMed ID: 37399108
[TBL] [Abstract][Full Text] [Related]
11. A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome.
Juarez M; Diaz N; Johnston GI; Nayar S; Payne A; Helmer E; Cain D; Williams P; Devauchelle-Pensec V; Fisher BA; Giacomelli R; Gottenberg JE; Guggino G; Kvarnström M; Mariette X; Ng WF; Rosas J; Sánchez Bursón J; Triolo G; Barone F; Bowman SJ
Rheumatology (Oxford); 2021 Mar; 60(3):1364-1375. PubMed ID: 32949140
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of total glucosides of peony in the treatment of primary Sjögren's syndrome: a multi-center, randomized, double-blinded, placebo-controlled clinical trial.
Liu X; Li X; Li X; Li Z; Zhao D; Liu S; Zhang M; Zhang F; Zhu P; Chen J; Wei W; Lin B; Zhou Y; Chen J; Pang Y; Zhang L; Sun X; Yu Z; Jia Y; Wang J; Sun W; Chiu F; Pang L; Wang G
Clin Rheumatol; 2019 Mar; 38(3):657-664. PubMed ID: 30280368
[TBL] [Abstract][Full Text] [Related]
13. Severe Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial.
Cornec D; Devauchelle-Pensec V; Mariette X; Jousse-Joulin S; Berthelot JM; Perdriger A; Puéchal X; Le Guern V; Sibilia J; Gottenberg JE; Chiche L; Hachulla E; Yves Hatron P; Goeb V; Hayem G; Morel J; Zarnitsky C; Dubost JJ; Saliou P; Pers JO; Seror R; Saraux A
Arthritis Care Res (Hoboken); 2017 Apr; 69(4):528-535. PubMed ID: 27390310
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjögren's syndrome: a randomized, phase 2, double-blind, placebo-controlled study.
Price E; Bombardieri M; Kivitz A; Matzkies F; Gurtovaya O; Pechonkina A; Jiang W; Downie B; Mathur A; Mozaffarian A; Mozaffarian N; Gottenberg JE
Rheumatology (Oxford); 2022 Nov; 61(12):4797-4808. PubMed ID: 35377447
[TBL] [Abstract][Full Text] [Related]
15. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab.
Meiners PM; Arends S; Brouwer E; Spijkervet FK; Vissink A; Bootsma H
Ann Rheum Dis; 2012 Aug; 71(8):1297-302. PubMed ID: 22258489
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
Chupp GL; Bradford ES; Albers FC; Bratton DJ; Wang-Jairaj J; Nelsen LM; Trevor JL; Magnan A; Ten Brinke A
Lancet Respir Med; 2017 May; 5(5):390-400. PubMed ID: 28395936
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of abatacept for the treatment of patients with primary Sjögren's syndrome.
Machado AC; Dos Santos LC; Fidelix T; Lekwitch I; Soares SB; Gasparini AF; Augusto JV; Junior NC; Trevisani VFM
Clin Rheumatol; 2020 Jan; 39(1):243-248. PubMed ID: 31420813
[TBL] [Abstract][Full Text] [Related]
18. A phase II investigator-initiated pilot study with low-dose cyclosporine A for the treatment of articular involvement in primary Sjögren's syndrome.
Kedor C; Zernicke J; Hagemann A; Gamboa LM; Callhoff J; Burmester GR; Feist E
Clin Rheumatol; 2016 Sep; 35(9):2203-10. PubMed ID: 27470087
[TBL] [Abstract][Full Text] [Related]
19. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
Peyrin-Biroulet L; Hart A; Bossuyt P; Long M; Allez M; Juillerat P; Armuzzi A; Loftus EV; Ostad-Saffari E; Scalori A; Oh YS; Tole S; Chai A; Pulley J; Lacey S; Sandborn WJ;
Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):128-140. PubMed ID: 34798039
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of iguratimod on patients with primary Sjögren's syndrome: a randomized, placebo-controlled clinical trial.
Shao Q; Wang S; Jiang H; Liu L
Scand J Rheumatol; 2021 Mar; 50(2):143-152. PubMed ID: 33118847
[No Abstract] [Full Text] [Related]
[Next] [New Search]
